{
  "Country": "PT",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Overall survival, progression-free survival, objective response rate, quality of life, adverse events"
    }
  ],
  "SourceType": "hta_submission"
}